# Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Article · Vera Bittner, Michael J. Szarek, Philip E. Aylward, Deepak L. Bhatt, Rafael Díaz, Jay M. Edelberg, Zlatko Fras, Shaun G. Goodman, Sigrun Halvorsen, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Virginie Loizeau, Patrick M. Moriarty, Angèle Moryusef, Robert C. Pordy, Matthew T. Roe, Peter Sinnaeve, Sotirios Tsimikas, Robert A. Vogel, Harvey Douglas White, Doron Zahger, Andreas Michael Zeiher, Philippe Gabríel Steg, Gregory G. Schwartz

- Archive id: doi:10.1016/j.jacc.2019.10.057
- Published: 2020-01-01
- Venue: Journal of the American College of Cardiology
- DOI: https://doi.org/10.1016/j.jacc.2019.10.057
- PMID: 31948641
- Citations: 572
- Source URL: https://doi.org/10.1016/j.jacc.2019.10.057
- PDF: https://www.sciencedirect.com/science/article/pii/S0735109719384645?via%3Dihub
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.